2022
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis
Garcia-Recio S, Hinoue T, Wheeler G, Kelly B, Garrido-Castro A, Pascual T, De Cubas A, Xia Y, Felsheim B, McClure M, Rajkovic A, Karaesmen E, Smith M, Fan C, Ericsson P, Sanders M, Creighton C, Bowen J, Leraas K, Burns R, Coppens S, Wheless A, Rezk S, Garrett A, Parker J, Foy K, Shen H, Park B, Krop I, Anders C, Gastier-Foster J, Rimawi M, Nanda R, Lin N, Isaacs C, Marcom P, Storniolo A, Couch F, Chandran U, Davis M, Silverstein J, Ropelewski A, Liu M, Hilsenbeck S, Norton L, Richardson A, Symmans W, Wolff A, Davidson N, Carey L, Lee A, Balko J, Hoadley K, Laird P, Mardis E, King T, Perou C. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nature Cancer 2022, 4: 128-147. PMID: 36585450, PMCID: PMC9886551, DOI: 10.1038/s43018-022-00491-x.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerBreast cancerHER2-targeted therapiesImmune cell infiltratesMetastatic breast tumorsLiver metastasesCell infiltrateLow-pass whole-genome sequencingSubtype changesT cellsEstrogen receptorTumor subtypesEndothelial contentBreast tumorsMetastasisCell-cell adhesion genesReduced expressionGlobal DNA methylationDNA methylation mechanismsFocal deletionsMolecular featuresWhole-genome sequencingCancerSubtypesRNA sequencing
2015
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, Perou CM, Winer EP, Hudis CA. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. Journal Of Clinical Oncology 2015, 34: 542-549. PMID: 26527775, PMCID: PMC4980567, DOI: 10.1200/jco.2015.62.1268.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCarcinomaEstrogen Receptor alphaFemaleGene ExpressionHumansImmunoglobulin GLapatinibMiddle AgedNeoadjuvant TherapyNeoplasm, ResidualPaclitaxelQuinazolinesReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneRNA, MessengerTrastuzumabTreatment OutcomeTumor MicroenvironmentTumor Suppressor Protein p53Young AdultConceptsPathologic complete response rateCALGB 40601Dual therapyIntrinsic subtypesHormone receptor-negative diseaseRandomized phase III trialHuman epidermal growth factor receptor 2End pointHER2-positive breast cancerEpidermal growth factor receptor 2Correlative end pointsDual HER2 blockadeHER2-positive diseaseComplete response ratePrimary end pointPhase III trialsProgression-free survivalReceptor-negative diseaseAddition of lapatinibGrowth factor receptor 2Immune cell signaturesFactor receptor 2Gene expression-based assaysMolecular featuresDual HER2